454 related articles for article (PubMed ID: 25407354)
1. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma.
Omar AI
J Vis Exp; 2014 Oct; (92):e51638. PubMed ID: 25407354
[TBL] [Abstract][Full Text] [Related]
2. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.
Stupp R; Wong ET; Kanner AA; Steinberg D; Engelhard H; Heidecke V; Kirson ED; Taillibert S; Liebermann F; Dbalý V; Ram Z; Villano JL; Rainov N; Weinberg U; Schiff D; Kunschner L; Raizer J; Honnorat J; Sloan A; Malkin M; Landolfi JC; Payer F; Mehdorn M; Weil RJ; Pannullo SC; Westphal M; Smrcka M; Chin L; Kostron H; Hofer S; Bruce J; Cosgrove R; Paleologous N; Palti Y; Gutin PH
Eur J Cancer; 2012 Sep; 48(14):2192-202. PubMed ID: 22608262
[TBL] [Abstract][Full Text] [Related]
3. Tumor treating fields: a novel and effective therapy for glioblastoma: mechanism, efficacy, safety and future perspectives.
Zhu P; Zhu JJ
Chin Clin Oncol; 2017 Aug; 6(4):41. PubMed ID: 28841803
[TBL] [Abstract][Full Text] [Related]
4. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
5. Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.
Narita Y
Jpn J Clin Oncol; 2013 Jun; 43(6):587-95. PubMed ID: 23585688
[TBL] [Abstract][Full Text] [Related]
6. The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes.
Rehman AA; Elmore KB; Mattei TA
Neurosurg Focus; 2015 Mar; 38(3):E14. PubMed ID: 25727223
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma.
Hainsworth JD; Shih KC; Shepard GC; Tillinghast GW; Brinker BT; Spigel DR
Clin Adv Hematol Oncol; 2012 Apr; 10(4):240-6. PubMed ID: 22706484
[TBL] [Abstract][Full Text] [Related]
8. Molecular characteristics and pathways of Avastin for the treatment of glioblastoma multiforme.
Spasic M; Chow F; Tu C; Nagasawa DT; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):417-27. PubMed ID: 22748654
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation.
Wong ET; Lok E; Swanson KD
Cancer Med; 2015 Mar; 4(3):383-91. PubMed ID: 25620708
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
11. The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.
Dirven L; van den Bent MJ; Bottomley A; van der Meer N; van der Holt B; Vos MJ; Walenkamp AM; Beerepoot LV; Hanse MC; Reijneveld JC; Otten A; de Vos FY; Smits M; Bromberg JE; Taal W; Taphoorn MJ;
Eur J Cancer; 2015 Jul; 51(10):1321-30. PubMed ID: 25899986
[TBL] [Abstract][Full Text] [Related]
12. Case of glioblastoma patient treated with tumor treating fields therapy at recurrence degenerating to sarcoma.
Majd P; O'Connell DE; Kim RC; Bota DA; Carrillo JA
CNS Oncol; 2017 Apr; 6(2):89-94. PubMed ID: 28303729
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma multiforme.
Cabrera AR; Cuneo KC; Vredenburgh JJ; Sampson JH; Kirkpatrick JP
J Natl Compr Canc Netw; 2012 Jun; 10(6):695-9. PubMed ID: 22679114
[TBL] [Abstract][Full Text] [Related]
14. FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival.
Schaub C; Greschus S; Seifert M; Waha A; Blasius E; Rasch K; Landwehr C; Mack F; Schäfer N; Stuplich M; Kebir S; Vilz B; Scheffler B; Boström J; Simon M; Urbach H; Glas M; Herrlinger U
Oncology; 2013; 85(3):191-5. PubMed ID: 24008924
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab as first-line therapy for glioblastoma.
Piccioni D; Lai A; Nghiemphu P; Cloughesy T
Future Oncol; 2012 Aug; 8(8):929-38. PubMed ID: 22894667
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
19. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
20. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]